TICKERNERD
Menu
ICCMICCMHealthcare · Medical Devices

ICCM Stock Forecast: IceCure Medical Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.35
−4.08% on the day

The 3 Wall Street analysts covering IceCure Medical Ltd. hold a median 12-month price target of $28 — +1091.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$8.1M
Ticker Nerd rank
38 / 100
Median analyst target
$28
Analysts covering
3
Total return, dividends reinvested
1W
−22.2%
1M
−30.1%
YTD
−87.2%
1Y
−91.1%
From 52W high
−93.4%
From 52W low
+10.3%
$2
$36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ICCM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IceCure Medical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Growth
89
Issuance
62
Revisions
57
Accruals
38
Volatility
36
Momentum
26
Quality
10
Value
1

Size (95): Smaller than most of the companies we track.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ICCM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICCM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26ICCMHigh $30Median $28Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $10Median $28High $30

The green dot is the last close — the median target sits +1091.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026Maxim GroupMaintainsBuy$3.00 → $1.00
7 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
29 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Sept 2024HC Wainwright & Co.ReiteratesBuy—
21 Aug 2024HC Wainwright & Co.MaintainsBuy—
2 July 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
29 May 2024HC Wainwright & Co.ReiteratesBuy—
16 Apr 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024HC Wainwright & Co.ReiteratesBuy—
20 Mar 2024Alliance Global PartnersMaintainsBuy—
20 Mar 2024HC Wainwright & Co.ReiteratesBuy—
5 Mar 2024HC Wainwright & Co.ReiteratesBuy—
29 Nov 2023HC Wainwright & Co.ReiteratesBuy$3.00
6 Sept 2023HC Wainwright & Co.ReiteratesBuy$3.00
15 Aug 2023Alliance Global PartnersMaintainsBuy$4.25 → $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICCM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ICCM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

IceCure Medical Ltd. (ICCM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 79% of US stocks

Price / sales
2.1×

Cheaper than 52% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
0.2×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
72.8%

Higher than 91% of US stocks

Earnings growth (YoY)
25.7%

Higher than 63% of US stocks

Gross margin
32.4%

Higher than 38% of US stocks

Operating margin
−487.8%

Higher than 8% of US stocks

Net margin
36.3%

Higher than 93% of US stocks

Returns & dividend
Return on equity
−228.3%

Higher than 6% of US stocks

Return on assets
−73.9%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ICCM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ICCMIceCure Medical Ltd.$8.1M
38
AIDX20/20 Biolabs, Inc.$6.8M
5
NVNOenVVeno Medical Corp.$6.7M
33
NXLNexalin Technology, Inc.$7.3M
38
PMIPicard Medical, Inc.$7.5M
33
CODXCo-Diagnostics, Inc.$7.6M
37
INBSIntelligent Bio Solutions, Inc.$7.6M
9

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IceCure Medical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ICCM news & analysis

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

PRNewsWire · 20 Aug 2026positive

IceCure Medical announced that the Institutional Review Board of West Cancer Center & Research Institute in Germantown, Tennessee, granted approval to commence its post-marketing ChoICE Study for ProSense cryoablation in the local treatment of low-risk breast cancer. Patient enrollment is expected to begin in the coming weeks.

Why it matters — This IRB approval clears the way for a new clinical site to begin enrolling patients in IceCure's ChoICE post-marketing study, expanding real-world data collection for its ProSense cryoablation platform in breast cancer treatment.

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

PRNewsWire · 13 Aug 2026positive

IceCure Medical highlighted two new peer-reviewed publications supporting the use of its ProSense cryoablation technology in breast cancer treatment de-escalation, including coverage of its FDA marketing authorization, updated treatment guidelines, and encouraging five-year ICE3 trial data. A second publication also explored cryoablation's role in treating axillary lymph node metastases.

Why it matters — The peer-reviewed publications reinforce the growing clinical acceptance and expanded potential applications of IceCure's cryoablation technology in breast cancer treatment.

IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

IceCure Medical Ltd. published the transcript of its Q2 2026 earnings call, hosted on Seeking Alpha, covering the company's second-quarter performance and management commentary for the period.

Why it matters — An ICCM watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly results and management's outlook.

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

PRNewsWire · 12 Aug 2026positive

IceCure Medical reported its financial and operational results for the six months ended June 30, 2026, citing 45% year-over-year revenue growth. The company also noted approximately 70% growth in its active installed base following U.S. FDA clearance, expansion of its U.S. commercial footprint, and a strong cash position.

Why it matters — The strong revenue growth and expansion of the installed base following FDA clearance signal ongoing commercial progress for ICCM's cryoablation technology.

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

PRNewsWire · 6 Aug 2026positive

IceCure Medical announced that Adventist Health Glendale in California has signed an agreement and received Institutional Review Board approval to become the first clinical site able to enroll patients for its post-marketing "ChoICE" study of the ProSense cryoablation system for low-risk breast cancer. The site will be led by breast surgeon Dr. Dennis Holmes.

Why it matters — This marks the first actively enrolling U.S. site for the company's post-marketing study of a treatment that received FDA marketing authorization in October 2025, expanding the study's footprint.

FAQ

Frequently asked questions about ICCM stock

What is the ICCM stock price forecast for 2026-2027?

The 3 Wall Street analysts covering IceCure Medical Ltd. have a median 12-month price target of $28, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ICCM stock a buy right now?

Of the 3 analysts covering IceCure Medical Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IceCure Medical Ltd. 38 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ICCM?

As at 22 Aug 2026, IceCure Medical Ltd. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will ICCM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1091.5% from the last close, and Ticker Nerd's factor model ranks IceCure Medical Ltd. 38 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ICCM stock forecast for 2030?

No analyst covering IceCure Medical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.

How has ICCM stock performed over the past year?

IceCure Medical Ltd. returned -91.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IceCure Medical Ltd. do?

IceCure Medical Ltd. is a commercial-stage medical device company specializing in minimally invasive cryoablation systems for the treatment of benign and cancerous tumors.

What is the latest news on ICCM?

The most recent item we track (PRNewsWire, 20 Aug 2026): "West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation". IceCure Medical announced that the Institutional Review Board of West Cancer Center & Research Institute in Germantown, Tennessee, granted approval to commence its post-marketing ChoICE Study for ProSense cryoablation in the local treatment of low-risk breast cancer. Patient enrollment is expected to begin in the coming weeks.

Company

About IceCure Medical Ltd.

IceCure Medical Ltd. is a commercial-stage medical device company specializing in minimally invasive cryoablation systems for the treatment of benign and cancerous tumors. The company develops and markets liquid-nitrogen-based technology that destroys tumors by freezing, offering a non-surgical option for local tumor control in areas such as breast, kidney, bone, and lung. Its flagship ProSense system is a single-probe cryoablation platform supported by associated disposables and is used in women’s health and interventional oncology for image-guided procedures that can be performed in office-based or CT-room settings. IceCure Medical also offers the IceSense3 system for various ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology, alongside the XSense and MultiSense systems designed for different tumor sizes and treatment needs. Incorporated in 2006 and headquartered in Caesarea, Israel, IceCure Medical plays a focused role in the medical equipment manufacturing sector by expanding access to cryoablation as a treatment option.

CEO Mr. Eyal Shamir · 67 employees · Israel · https://www.icecure-medical.com